- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05432778
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients (CYPHER-TXPilot)
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study
CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation and commonly presents as an asymptomatic viral replication. Viral syndrome or tissue-invasive disease (gastroenteritis, pneumonitis, myocarditis or meningitis) are much less common. Even though CMV infection is generally treatable with virostatic therapy and/or CMV-specific immunoglobulins, direct effects of CMV infection (viral syndrome and tissue-invasive disease) and general and transplant-specific indirect effects of CMV infection have been associated with significant morbidity and mortality in HTX patient population, mainly due to graft loss, development of malignancies, or opportunistic infections. According to the latest consensus paper on CMV prophylaxis and treatment in solid organ transplant recipients, valgancyclovir (or its active form gancyclovir) represents a virostatic therapy of choice for CMV prophylaxis and treatment after HTX. However, valgancyclovir has an array of side effects including hematological (leukopenia, neutropenia, anemia, thrombocytopenia), neurologic (headache, insomnia), gastrointestinal (decreased appetite, diarrhea, vomiting and dyspepsia) and psychiatric (depression) disorders. These can either expose HTX patients to additional complications (e.g. leukopenia and/or neutropenia can result in systemic fungal infections), decrease patients' quality of life, or mandate a decrease in valgancyclovir dose, which exposes patients to an increased risk for CMV reactivation. Recently, letermovir (a novel CMV viral terminase inhibitor), was approved for CMV prophylaxis in allogeneic bone marrow transplant recipients as the placebo-controlled study showed that significantly less patients, treated with letermovir, developed CMV disease (37% vs. 60%; P<0.001) and there was also a trend towards lower all-cause mortality. Data on bone marrow transplant recipients additionally suggest that letermovir is generally well tolerated with side effects limited to mild gastrointestinal symptoms (diarrhea, nausea). Importantly, myelosuppresive side effects of letermovir occur very rarely. Some encouraging data does exist on the use of letermovir in kidney transplant recipients, where a recently published proof-of-concept trial (N=27) suggested comparable safety and efficacy of leteremovir (N=18) and valgancyclovir (N=9): both treatment regimens resulted in similar time-course of viral load reduction and viral clearance and were well tolerated in terms of adverse events. Currently, a Phase III clinical trial is ongoing in renal transplant recipients (Clinicaltrials.gov: NCT03443869) to confirm this pilot data. However, to date, there is no published data on the use of letermovir in patients after HTX.
Based on the results in kidney transplantation, the aim of this pilot study is thus to evaluate the effects of letermovir-based CMV prophylaxis in heart transplant recipients.
The primary objective of the study is to investigate the efficacy of letermovir-based CMV prophylaxis in patients after heart transplantation.
The secondary objectives of the study are:
- to investigate the tolerability of letermovir-based CMV prophylaxis in patients after heart transplantation.
- to explore the potential correlation between letermovir-based CMV prophylaxis and restitution of cell-regulated immunity in patients after heart transplantation.
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Gregor Poglajen, MD, PhD
- Phone Number: +38615228671
- Email: gregor.poglajen@kclj.si
Study Contact Backup
- Name: Bojan Vrtovec, MD, PhD
- Phone Number: +38615222844
- Email: bojan.vrtovec@kclj.si
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- Recruiting
- University Medical Center Ljubljana
-
Contact:
- Bojan Vrtovec, MD, PhD
- Phone Number: +38615221163
- Email: mateja.lani@kclj.si
-
Sub-Investigator:
- Gregor Poglajen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- heart transplant recipient (new)
- moderate (D+/R+ and D-/R+) or high (D+/R-) risk CMV serostatus
- signed informed consent for participation in the study
Exclusion Criteria:
- short-term mechanical circulatory support prior HTX
- ongoing CMV infection/disease
- D-/R- CMV serostatus
- heart re-transplantation
need for intensified immunosuppression protocol
- >20% cytolytic alloantibodies prior transplant
- perioperative (within 7 days after HTX) allograft rejection > 1R
- immunoinduction with ATG
- pregnancy
- active participation in another interventional clinical trial
- know hypersensitivity to letermovir
- known hypersensitivity to valgancyclovir
- known hematological disorders (apart from anemia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Group
All patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available).
|
Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available).
n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
|
No Intervention: Control Group
Patients in Controls will receive standard-of-care virostatic prophylaxis with valgancyclovir 450 mg bid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of early CMV infections/disease during virostatic prophylaxis.
Time Frame: baseline - 12 months
|
The rate of early CMV infections/disease during virostatic prophylaxis.
|
baseline - 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of leukopenia during virostatic prophylaxis
Time Frame: baseline - 12 months
|
The rate of leukopenia during virostatic prophylaxis
|
baseline - 12 months
|
The rate of neutropenia during virostatic prophylaxis
Time Frame: baseline - 12 months
|
The rate of neutropenia during virostatic prophylaxis
|
baseline - 12 months
|
The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter.
Time Frame: baseline - 12 months
|
The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter.
|
baseline - 12 months
|
The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis
Time Frame: baseline - 12 months
|
The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis
|
baseline - 12 months
|
The rate of CMV resistance to virostatic therapy
Time Frame: baseline - 12 months
|
The rate of CMV resistance to virostatic therapy
|
baseline - 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bojan Vrtovec, MD, PhD, Advanced Heart Failure and Transplantation Center, Universtiy Medical Center Ljubljana, Slovenia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01 (Miami VAHS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV Viremia
-
Hospital Israelita Albert EinsteinRecruiting
-
University of MinnesotaCompletedCMV Viremia | EBV ViremiaUnited States
-
University of Alabama at BirminghamRecruitingCmv Congenital | CMV ViremiaBrazil
-
Hospital do Rim e HipertensãoEnrolling by invitationCMV Infection | CMV ViremiaBrazil
-
Atara BiotherapeuticsNo longer available
-
Memorial Sloan Kettering Cancer CenterRecruitingCMV Infection | Persistent CMV ViremiaUnited States
-
Peking University People's HospitalRecruitingTransplantation Infection | CMV ViremiaChina
-
University of Wisconsin, MadisonUniversity of Wisconsin Carbone Cancer Center (UWCCC)RecruitingCytomegalovirus Infections | Opportunistic Infections | CMV Infection | CMV ViremiaUnited States
-
Peking University People's HospitalUnknownAcute Leukemia | Hematopoietic Stem Cell Transplantation | CMV ViremiaChina
-
Banc de Sang i TeixitsHospital Universitario La Fe; Vall d'Hebron Institute of OncologyCompletedCMV Viremia | Immunosuppression-related Infectious DiseaseSpain
Clinical Trials on Letermovir Pill
-
The First Affiliated Hospital of Soochow UniversityRecruitingHematopoietic Stem Cell Transplantation | CMV InfectionChina
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCRecruitingCMV | CMV Infection | Hematopoietic Cell TransplantUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionUnited States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | Cytomegalovirus | CMVUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCytomegalovirus InfectionFrance
-
Maimónides Biomedical Research Institute of CórdobaMERCK SHARP & DOHME DE ESPAÑA S.A.Not yet recruitingInfections, CytomegalovirusSpain
-
University of PennsylvaniaMerck Sharp & Dohme LLCRecruitingCytomegalovirus Infections | Transplant-Related DisorderUnited States
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Hospital do Rim e HipertensãoNot yet recruiting